Chinese researchers successful in curing diabetes

In a significant medical development, researchers in China have reported success in using stem cell therapy to reverse both type 1 and type 2 diabetes in human patients.

The experimental treatment focuses on restoring the body’s own ability to produce insulin, shifting the approach from lifelong disease management to potentially correcting the underlying cause of diabetes.

In one case involving type 2 diabetes, scientists generated insulin-producing pancreatic cells in the laboratory using advanced stem cell techniques. These newly created cells were transplanted into a patient, who subsequently no longer needed insulin injections or other glucose-lowering medications.

Stem cells, often described as versatile foundational cells, can develop into various specialised cell types. By directing them to become pancreatic islet cells, which are responsible for insulin production, researchers were able to replace damaged or dysfunctional cells. After transplantation, the engineered cells began functioning like healthy pancreatic tissue, enabling natural blood sugar regulation.

Traditional diabetes treatment typically centres on managing blood glucose levels through diet, exercise, medication, and insulin therapy. While these methods help keep blood sugar within a safe range, they do not repair the damaged insulin-producing cells in type 1 diabetes or fully resolve insulin resistance in type 2 diabetes. Stem cell therapy, by contrast, seeks to restore or replace the affected cells themselves.

Chinese researchers have also previously reported progress in treating type 1 diabetes. In an earlier case, a young patient who had relied on insulin injections for years began producing her own insulin after receiving transplanted islet cells derived from her own reprogrammed fat cells. She remained free from insulin therapy for more than a year following the procedure.

Although type 1 and type 2 diabetes differ in their causes, positive outcomes in both conditions underscore the expanding potential of regenerative medicine in diabetes care.

More than 580 million people worldwide are living with diabetes. If validated through larger clinical trials, stem cell-based therapies could ease the daily demands of disease management and reduce the risk of complications such as cardiovascular disease, kidney damage, and nerve disorders.

Researchers emphasise, however, that isolated cases do not amount to a definitive cure. Extensive trials are still required to establish long-term safety, effectiveness, and durability before the treatment can become widely available.